ReviewFrontiers in immunology2024
IFNs in host defence and parasite immune evasion during
Review in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 13 citations in OpenAlex.
- Rapid and accessible tumor necrosis factor alpha detection using digital nanoparticle sensors towards point-of-care cytokine monitoring.Sensors and actuators. B, Chemical · 2026Article
- Nasal Nanoparticle Vaccine Induces a Cross-Strain T-Cell Immunity AgainstPharmaceutics · 2026Article
- Protective Effect Against Acute Experimental Toxoplasmosis Conferred by Intranasal Immunisation withVaccines · 2026Article
- Modulation of host lung immunity in Pneumocystis pneumonia: a review of current concepts and future prospects for novel adjunctive immune-based therapies.Journal of immunology (Baltimore, Md. : 1950) · 2026Review
- IL-33/ST2 Signaling Protects the Heart by Restraining Inflammation and Parasite Burden duringACS infectious diseases · 2026Article
- Nitric Oxide Synthase 2 (NOS2) Gene Polymorphisms Association With Risk of Pulmonary Tuberculosis (PTB): A Case-Control Study.BioMed research international · 2026Article
- Endogenous Amphiregulin promotes muscle repair and function through expansion of fibro-adipogenic progenitors during chronicFrontiers in microbiology · 2026Article
- Recombinant ROP8 antigen: diagnostics, immunogenicity, and therapeutic targeting in toxoplasmosis.Frontiers in immunology · 2026Article
- Dense granule proteins: key mediators ofFrontiers in medicine · 2026Review
- Interferon-induced transmembrane proteins: membrane gatekeepers of fusion and infection.Frontiers in cellular and infection microbiology · 2026Review
- Article
- Toxoplasma gondii-induced adverse pregnancy outcomes: insight into the inhibitory role of Trem2 on TLR4/TRAF6/JNK signaling pathway.Parasites & vectors · 2025Article
- IL-24 Is a Promising Molecular Adjuvant for Enhancing Protective Immunity Induced by DNA Vaccination AgainstMicroorganisms · 2025Article
- Article
- Interferons andFrontiers in immunology · 2025Article
- Mutual regulations betweenFrontiers in immunology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Interferons (IFNs) are a family of cytokines with diverse functions in host resistance to pathogens and in immune regulation. Type II IFN, i.e. IFN-γ, is widely recognized as a major mediator of resistance to intracellular pathogens, including the protozoan
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.